Liquid-based cytology
This article was originally published in The Gray Sheet
Executive Summary
Technology is recommended by NICE in 1LBC guidance as the primary means of processing Pap smear samples in the UK's cervical screening program. The UK body released a final appraisal on the procedure in August (2"The Gray Sheet" Aug. 18, 2003, In Brief)...
You may also be interested in...
NICE endorses liquid-based cytology
National Institute for Clinical Excellence final appraisal determination issued Aug. 15 recommends using the technology as the primary means of processing samples in the UK's cervical screening program. Implementation of the policy - representing 4 mil. annual tests - should take about three to five years. The decision was applauded by LBC stakeholders Cytyc (ThinPrep) and TriPath (SurePath). NICE issued a preliminary recommendation in April (1"The Gray Sheet" April 21, 2003, p. 6)...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.